Human papilloma virus, DNA methylation and microRNA expression in cervical cancer (Review)

Oncology Reports

Volumn 31, Issue 6, 2014, Pages 2467-2476

  Jiménez Wences, Hilda ^a   Peralta Zaragoza, Oscar ^b   Fernández Tilapa, Gloria ^a  

^a UNIVERSIDAD AUTÓNOMA DE GUERRERO   (Mexico)

^b INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

Author keywords

Cervical cancer; Human papilloma virus; Methylation; miRNAs

Indexed keywords

DNA METHYLTRANSFERASE 1; MICRORNA; MICRORNA 1246; MICRORNA 126; MICRORNA 143; MICRORNA 145; MICRORNA 155; MICRORNA 182; MICRORNA 183; MICRORNA 195; MICRORNA 196A; MICRORNA 203; MICRORNA 20A; MICRORNA 21; MICRORNA 210; MICRORNA 218; MICRORNA 221; MICRORNA 2392; MICRORNA 27A; MICRORNA 3147; MICRORNA 3162-5P; MICRORNA 34A; MICRORNA 368; MICRORNA 4484; MICRORNA 497; PROTEIN E6; PROTEIN E7; PROTEIN P53; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS DNA;

CARCINOGENESIS; DISEASE COURSE; DNA METHYLATION; DNA SEQUENCE; DOWN REGULATION; EPIGENETICS; FEMALE; GENE CONTROL; GENE EXPRESSION; GENE SILENCING; GENETIC DISORDER; GENOTYPE; HELICOBACTER PYLORI; HISTONE ACETYLATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; NONHUMAN; ONCOGENE; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; TUMOR SUPPRESSOR GENE; UPREGULATION; UTERINE CERVIX CANCER; WART VIRUS; COMPLICATION; GENE EXPRESSION REGULATION; GENETICS; PAPILLOMA VIRUS; PATHOGENICITY; PATHOLOGY; UTERINE CERVIX TUMOR; VIROLOGY;

DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 84902122783     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3142     Document Type: Review

References (95)

1. Wang X, Tang S, Le SY, et al: Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One 3: e2557, 2008.
2. Wilting SM, van Boerdonk RA, Henken FE, et al: Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer. Mol Cancer 9: 167, 2010.
3. Yang HJ: Aberrant DNA methylation in cervical carcinogenesis. Chin J Cancer 32: 42-48, 2013.
4. Faridi R, Zahra A, Khan K and Idrees M: Oncogenic potential of human papillomavirus (HPV) and its relation with cervical cancer. Virol J 8: 269, 2011.
5. Lui WO, Pourmand N, Patterson BK and Fire A: Patterns of known and novel small RNAs in human cervical cancer. Cancer Res 67: 6031-6043, 2007. (Pubitemid 47037482)
6. Whiteside MA, Siegel EM and Unger ER: Human papillomavirus and molecular considerations for cancer risk. Cancer 113 (Supp 10): 2981-2994, 2008.
7. Saavedra KP, Brebi PM and Roa JC: Epigenetic alterations in preneoplastic and neoplastic lesions of the cervix. Clin Epigenetics 4: 13, 2012.
8. Lechner M, Fenton T, West J, et al: Identification and functional validation of HPV-mediated hypermethylation in head and neck squamous cell carcinoma. Genome Med 5: 15, 2013.
9. Chaiwongkot A, Vinokurova S, Pientong C, et al: Differential methylation of E2 binding sites in episomal and integrated HPV 16 genomes in preinvasive and invasive cervical lesions. Int J Cancer 132: 2087-2094, 2013.
10. Das P, Thomas A, Mahantshetty U, Shrivastava SK, Deodhar K and Mulherkar R: HPV genotyping and site of viral integration in cervical cancers in Indian women. PLoS One 7: e41012, 2012.
11. Martinez I, Gardiner AS, Board KF, Monzon FA, Edwards RP and Khan SA: Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells. Oncogene 27: 2575-2582, 2008. (Pubitemid 351550884)
12. Zheng ZM and Wang X: Regulation of cellular miRNA expression by human papillomaviruses. Biochim Biophys Acta 1809: 668-677, 2011.
13. Rao Q, Shen Q, Zhou H, Peng Y, Li J and Lin Z: Aberrant microRNA expression in human cervical carcinomas. Med Oncol 29: 1242-1248, 2012.
14. Li Y, Liu J, Yuan C, Cui B, Zou X and Qiao Y: High-risk human papillomavirus reduces the expression of microRNA-218 in women with cervical intraepithelial neoplasia. J Int Med Res 38: 1730-1736, 2010.
15. Dreher A, Rossing M, Kaczkowski B, Nielsen FC and Norrild B: Differential expression of cellular microRNAs in HPV-11 transfected cells. An analysis by three different array platforms and qRT-PCR. Biochem Biophys Res Commun 403: 357-362, 2010.
16. Sato F, Tsuchiya S, Meltzer SJ and Shimizu K: MicroRNAs and epigenetics. FEBS J 278: 1598-1609, 2011.
17. Colón-López V, Ortiz AP and Palefsky J: Burden of human papillomavirus infection and related comorbidities in men: implications for research, disease prevention and health promotion among Hispanic men. P R Health Sci J 29: 232-240, 2010.
18. Chaturvedi AK: Beyond cervical cancer: burden of other HPV-related cancers among men and women. J Adolesc Health 46: S20-S26, 2010.
19. Lu Q, Ma D and Zhao S: DNA methylation changes in cervical cancers. Methods Mol Biol 863: 155-176, 2012.
20. Botezatu A, Goia-Rusanu CD, Iancu IV, et al: Quantitative analysis of the relationship between microRNA-124a, -34b and -203 gene methylation and cervical oncogenesis. Mol Med Rep 4: 121-128, 2011.
21. Sasagawa T, Takagi H and Makinoda S: Immune responses against human papillomavirus (HPV) infection and evasion of host defense in cervical cancer. J Infect Chemother 18: 807-815, 2012.
22. Correa de Adjounian MF, Adjounian H and Adjounian SH: Silenciamiento de genes mediante RNA interferencia: consid eraciones sobre el mecanismo y diseño de los sistemas efectores. AVFT 27: 22-25, 2008.
23. Rouhi A, Mager DL, Humphries RK and Kuchenbauer F: MiRNAs, epigenetics, and cancer. Mamm Genome 19: 517-525, 2008.
24. Bock C: Epigenetic biomarker development. Epigenomics 1: 99-110, 2009.
25. Yang N, Coukos G and Zhang L: MicroRNA epigenetic alterations in human cancer: one step forward in diagnosis and treatment. Int J Cancer 122: 963-968, 2008. (Pubitemid 351213992)
26. Valeri N, Vannini I, Fanini F, Calore F, Adair B and Fabbri M: Epigenetics, miRNAs, and human cancer: a new chapter in human gene regulation. Mamm Genome 20: 573-580, 2009.
27. Ehrlich M: DNA hypomethylation in cancer cells. Epigenomics 1: 239-259, 2009.
28. Henken FE, Wilting SM, Overmeer RM, et al: Sequential gene promoter methylation during HPV-induced cervical carcino genesis. Br J Cancer 97: 1457-1464, 2007. (Pubitemid 350114795)
29. Berdasco M and Esteller M: Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev Cell 19: 698-711, 2010.
30. Lopez-Serra P and Esteller M: DNA methylation-associated silencing of tumor-suppressor microRNAs in cancer. Oncogene 31: 1609-1622, 2012.
31. Saito Y and Jones PA: Epigenetic activation of tumor suppressor microRNAs in human cancer cells. Cell Cycle 5: 2220-2222, 2006. (Pubitemid 44546557)
32. Lujambio A and Esteller M: CpG island hypermethylation of tumor suppressor microRNAs in human cancer. Cell Cycle 6: 1455-1459, 2007.
33. Toyota M, Suzuki H, Sasaki Y, et al: Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res 68: 4123-4132, 2008.
34. Huang YW, Liu JC, Deatherage DE, et al: Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer Res 69: 9038-9046, 2009.
35. Leonard SM, Wei W, Collins SI, et al: Oncogenic human papillomavirus imposes an instructive pattern of DNA methylation changes which parallel the natural history of cervical HPV infection in young women. Carcinogenesis 33: 1286-1293, 2012.
36. Missaoui N, Hmissa S, Dante R and Frappart L: Global DNA methylation in precancerous and cancerous lesions of the uterine cervix. Asian Pac J Cancer Prev 11: 1741-1744, 2010.
37. Kalantari M, Calleja-Macias IE, Tewari D, et al: Conserved methylation patterns of human papillomavirus type 16 DNA in asymptomatic infection and cervical neoplasia. J Virol 78: 12762-12772, 2004. (Pubitemid 39507784)
38. Burgers WA, Blanchon L, Pradhan S, et al: Viral oncoproteins target the DNA methyltransferases. Oncogene 26: 1650-1655, 2007. (Pubitemid 46398736)
39. Au Yeung CL, Tsang WP, Tsang TY, Co NN, Yau PL and Kwok TT: HPV-16 E6 upregulation of DNMT1 through repression of tumor suppressor p53. Oncol Rep 24: 1599-1604, 2010.
40. McCabe MT, Davis JN and Day ML: Regulation of DNA methyltransferase 1 by the pRb/E2F1 pathway. Cancer Res 65: 3624-3632, 2005. (Pubitemid 40616339)
41. Richards KL, Zhang B, Baggerly KA, et al: Genome-wide hypomethylation in head and neck cancer is more pronounced in HPV-negative tumors and is associated with genomic instability. PLoS One 4: e4941, 2009.
42. Lin RK, Wu CY, Chang JW, et al: Dysregulation of p53/Sp1 control leads to DNA methyltransferase-1 overexpression in lung cancer. Cancer Res 70: 5807-5817, 2010.
43. Jin-Tao W, Ling D, Shi-Wen J, et al: Folate deficiency and aberrant expression of DNA methyltransferase 1 were associated with cervical cancerization. Curr Pharm Des: Jul 19, 2013 (Epub ahead of print).
44. Nambaru L, Meenakumari B, Swaminathan R and Rajkumar T: Prognostic significance of HPV physical status and integration sites in cervical cancer. Asian Pac J Cancer Prev 10: 355-360, 2009.
45. Turan T, Kalantari M, Cuschieri K, Cubie HA, Skomedal H and Bernard HU: High-throughput detection of human papil lomavirus-18 L1 gene methylation, a candidate biomarker for the progression of cervical neoplasia. Virology 361: 185-193, 2007. (Pubitemid 46553810)
46. Davis-Dusenbery BN and Hata A: MicroRNA in cancer: the involvement of aberrant microRNA biogenesis regulatory pathways. Genes Cancer 1: 1100-1114, 2010.
47. Shivdasani RA: MicroRNAs: regulators of gene expression and cell differentiation. Blood 108: 3646-3653, 2006.
48. Cho WC: OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer 6: 60, 2007.
49. Pavicic W, Perkiö E, Kaur S, et al: Altered methylation at microRNA-associated CpG islands in hereditary and sporadic carcinomas: a methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA)-based approach. Mol Med 17: 726-735, 2011.
50. Shen Y, Li Y, Ye F, et al: Identification of miR-23a as a novel microRNA normalizer for relative quantification in human uterine cervical tissues. Exp Mol Med 43: 358-366, 2011.
51. Greco D, Kivi N, Qian K, et al: Human papillomavirus 16 E5 modulates the expression of host microRNAs. PLoS One 6: e21646, 2011.
52. So AY, Jung JW, Lee S, Kim HS and Kang KS: DNA methyltransferase controls stem cell aging by regulating BMI1 and EZH2 through microRNAs. PLoS One 6: e19503, 2011.
53. Ferreira HJ, Heyn H, Moutinho C, et al: CpG island hypermethylation- associated silencing of small nucleolar RNAs in human cancer. RNA Biol 9: 881-890, 2012.
54. Hata A and Davis BN: Control of microRNA biogenesis by TGFβ signaling pathway - a novel role of Smads in the nucleus. Cytokine Growth Factor Rev 20: 517-521, 2009.
55. Fazi F and Nervi C: MicroRNA: basic mechanisms and tran scriptional regulatory networks for cell fate determination. Cardiovasc Res 79: 553-561, 2008.
56. Wang G, Wang Y, Teng M, Zhang D, Li L and Liu Y: Signal transducers and activators of transcription-1 (STAT1) regulates microRNA transcription in interferon γ-stimulated HeLa cells. PLoS One 5: e11794, 2010.
57. Bandres E, Agirre X, Bitarte N, et al: Epigenetic regulation of microRNA expression in colorectal cancer. Int J Cancer 125: 2737-2743, 2009.
58. Siomi H and Siomi MC: Posttranscriptional regulation of microRNA biogenesis in animals. Mol Cell 38: 323-332, 2010.
59. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ and Kerin MJ: MicroRNAs as novel biomarkers for breast cancer. J Oncol 2009: 950201, 2009.
60. Chen J, Yao D, Li Y, et al: Serum microRNA expression levels can predict lymph node metastasis in patients with early-stage cervical squamous cell carcinoma. Int J Mol Med 32: 557-567, 2013.
61. Gocze K, Gombos K, Juhasz K, Kovacs K, Kajtar B, Benczik M, et al: Unique microRNA expression profiles in cervical cancer. Anticancer Res 33: 2561-2567, 2013.
62. Wilting SM, Snijders PJ, Verlaat W, et al: Altered microRNA expression associated with chromosomal changes contributes to cervical carcinogenesis. Oncogene 32: 106-116, 2013.
63. Huang L, Lin JX, Yu YH, Zhang MY, Wang HY and Zheng M: Downregulation of six microRNAs is associated with advanced stage, lymph node metastasis and poor prognosis in small cell carcinoma of the cervix. PLoS One 7: e33762, 2012.
64. Cheung TH, Man KN, Yu MY, et al: Dysregulated microRNAs in the pathogenesis and progression of cervical neoplasm. Cell Cycle 11: 2876-2884, 2012.
65. Ma D, Zhang YY, Guo YL, Li ZJ and Geng L: Profiling of microRNA-mRNA reveals roles of microRNAs in cervical cancer. Chin Med J 125: 4270-4276, 2012.
66. Pereira PM, Marques JP, Soares AR and Carreto L and Santos MA: MicroRNA expression variability in human cervical tissues. PLoS One 5: e11780, 2010.
67. Hu X, Schwarz JK, Lewis JS Jr, et al: A microRNA expression signature for cervical cancer prognosis. Cancer Res 70: 1441-1448, 2010.
68. Lee JW, Choi CH, Choi JJ, et al: Altered microRNA expression in cervical carcinomas. Clin Cancer Res 14: 2535-2542, 2008.
69. Yao T, Rao Q, Liu L, et al: Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in cervical cancer. Virol J 10: 175, 2013.
70. Wilting SM, Verlaat W, Jaspers A, et al: Methylation-mediated transcriptional repression of microRNAs during cervical carcinogenesis. Epigenetics 8: 220-228, 2013.
71. Kalimutho M, Di Cecilia S, Del Vecchio Blanco G, et al : Epigenetically silenced miR-34b/c as a novel faecal-based screening marker for colorectal cancer. Br J Cancer 104: 1770-1778, 2011.
72. Vogt M, Munding J, Grüner M, et al: Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas. Virchows Arch 458: 313-322, 2011.
73. Zhang Y, Wang X, Xu B, et al: Epigenetic silencing of miR-126 contributes to tumor invasion and angiogenesis in colorectal cancer. Oncol Rep 30: 1976-1984, 2013.
74. Zhu A, Xia J, Zuo J, et al : MicroRNA-148a is silenced by hypermethylation and interacts with DNA methyltransferase 1 in gastric cancer. Med Oncol 29: 2701-2709, 2012.
75. Tsai KW, Wu CW, Hu LY, et al: Epigenetic regulation of miR-34b and miR-129 expression in gastric cancer. Int J Cancer 129: 2600-2610, 2011.
76. Tsai KW, Liao YL, Wu CW, et al: Aberrant hypermethylation of miR-9 genes in gastric cancer. Epigenetics 6: 1189-1197, 2011.
77. Kim K, Lee HC, Park JL, et al: Epigenetic regulation of microRNA-10b and targeting of oncogenic MAPRE1 in gastric cancer. Epigenetics 6: 740-751, 2011.
78. Guo LH, Li H, Wang F, Yu J and He JS: The tumor suppressor roles of miR-433 and miR-127 in gastric cancer. Int J Mol Sci 14: 14171-14184, 2013.
79. Deng H, Guo Y, Song H, et al: MicroRNA-195 and microRNA-378 mediate tumor growth suppression by epigenetical regulation in gastric cancer. Gene 518: 351-359, 2013.
80. Yan-Fang T, Jian N, Jun L, et al: The promoter of miR-663 is hypermethylated in Chinese pediatric acute myeloid leukemia (AML). BMC Med Genet 14: 74, 2013.
81. Köhler CU, Bryk O, Meier S, et al: Analyses in human urothelial cells identify methylation of miR-152, miR-200b and miR-10a genes as candidate bladder cancer biomarkers. Biochem Biophys Res Commun 438: 48-53, 2013.
82. Datta J, Kutay H, Nasser MW, et al: Methylation mediated silencing of microRNA-1 gene and its role in hepatocellular carcinogenesis. Cancer Res 68: 5049-5058, 2008.
83. Jung CJ, Iyengar S, Blahnik KR, et al: Epigenetic modulation of miR-122 facilitates human embryonic stem cell self-renewal and hepatocellular carcinoma proliferation. PLoS One 6: e27740, 2011.
84. He Y, Cui Y, Wang W, et al: Hypomethylation of the hsa-miR-191 locus causes high expression of hsa-mir-191 and promotes the epithelial-to-mesenchymal transition in hepatocellular carcinoma. Neoplasia 13: 841-853, 2011.
85. Zhang Y, Yan LX, Wu QN, et al: miR-125b is methylated and functions as a tumor suppressor by regulating the ETS1 proto-oncogene in human invasive breast cancer. Cancer Res 71: 3552-3562, 2011.
86. Augoff K, McCue B, Plow EF and Sossey-Alaoui K: miR-31 and its host gene lncRNA LOC554202 are regulated by promoter hypermethylation in triple-negative breast cancer. Mol Cancer 11: 5, 2012.
87. Vrba L, Muñoz-Rodríguez JL, Stampfer MR and Futscher BW: miRNA gene promoters are frequent targets of aberrant DNA methylation in human breast cancer. PLoS One 8: e54398, 2013.
88. Rauhala HE, Jalava SE, Isotalo J, et al: miR-193b is an epige netically regulated putative tumor suppressor in prostate cancer. Int J Cancer 127: 1363-1372, 2010.
89. Hulf T, Sibbritt T, Wiklund ED, et al: Epigenetic-induced repression of microRNA-205 is associated with MED1 activation and a poorer prognosis in localized prostate cancer. Oncogene 32: 2891-2899, 2013.
90. Formosa A, Lena AM, Markert EK, et al: DNA methylation silences miR-132 in prostate cancer. Oncogene 32: 127-134, 2013.
91. Heller G, Weinzierl M, Noll C, et al: Genome-wide miRNA expression profiling identifies miR-9-3 and miR-193a as targets for DNA methylation in non-small cell lung cancers. Clin Cancer Res 18: 1619-1629, 2012.
92. Incoronato M, Urso L, Portela A, et al: Epigenetic regulation of miR-212 expression in lung cancer. PLoS One 6: e27722, 2011.
93. Kitano K, Watanabe K, Emoto N, et al: CpG island methylation of microRNAs is associated with tumor size and recurrence of non-small-cell lung cancer. Cancer Sci 102: 2126-2131, 2011.
94. Wang Z, Chen Z, Gao Y, et al: DNA hypermethylation of microRNA-34b/c has prognostic value for stage I non-small cell lung cancer. Cancer Biol Ther 11: 490-496, 2011.
95. Wong KY1, Liang R, So CC, Jin DY, Costello JF and Chim CS: Epigenetic silencing of MIR203 in multiple myeloma. Br J Haematol 154: 569-578, 2011.